SCHEMBL5732625

SCHEMBL5732625

COP(=O)(CC(=O)c1cccc(C=C2CCOCC2)c1)OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ SRD5A1 P18405 1/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ CTNNB1 P35222 2/20 0.33
▸ WNT3A P56704 2/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ OGA O60502 2/20 0.32
▸ GRIN2D O15399 1/20 0.32
▸ GRIN3B O60391 1/20 0.32
▸ GRIN1 Q05586 1/20 0.32
▸ GRIN2A Q12879 1/20 0.32
▸ GRIN2B Q13224 1/20 0.32
▸ GRIN2C Q14957 1/20 0.32
▸ GRIN3A Q8TCU5 1/20 0.32
▸ FAAH O00519 2/20 0.32
▸ PDE4D Q08499 2/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5732630 0.83 ALDH1A1 (0.34) LMNAPOLBSRD5A1L3MBTL1OGA
SCHEMBL5733123 0.76 POLB (0.44) LMNAPOLBGRIN2DGRIN3BGRIN1
SCHEMBL5733118 0.76 POLB (0.44) LMNAPOLBGRIN2DGRIN3BGRIN1
SCHEMBL23684304 0.76 UNG (0.53) LMNASRD5A1CYP2C9TDP1
SCHEMBL30260159 0.73 SLC7A5 (0.41) LMNASRD5A1L3MBTL1GRIN2DGRIN3B
SCHEMBL23684239 0.73 SLC7A5 (0.41) LMNASRD5A1L3MBTL1GRIN2DGRIN3B
SCHEMBL5732970 0.72 LMNA (0.38) LMNAPOLBPDE4DPDE4APDE4B
SCHEMBL5732711 0.71 POLB (0.50) LMNAPOLBCTNNB1FAAHALDH1A1
SCHEMBL5733742 0.70 NPC1 (0.59) LMNAALDH1A1
SCHEMBL10682789 0.70 ERCC5 (0.50) LMNAPOLBCYP2C9CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1409455-B1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2006-01-04 — — EP disclosed
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 — — US disclosed
EP-1409455-A1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-21 — — EP disclosed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 — — US disclosed
WO-2003008377-A1 PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-01-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction PTGER4, FFAR4, PTGER1 LMNA 3569/4885POLB 3426/4885SRD5A1 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback